- Home
- WSBF vs VNDA Comparison
WSBF vs VNDA Comparison
Compare WSBF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- VNDA
- Stock Information
- Founded
- WSBF 1921
- VNDA 2002
- Country
- WSBF United States
- VNDA United States
- Employees
- WSBF N/A
- VNDA N/A
- Industry
- WSBF Savings Institutions
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- VNDA Health Care
- Exchange
- WSBF Nasdaq
- VNDA Nasdaq
- Market Cap
- WSBF 288.1M
- VNDA 289.0M
- IPO Year
- WSBF N/A
- VNDA 2006
- Fundamental
- Price
- WSBF $15.78
- VNDA $5.28
- Analyst Decision
- WSBF
- VNDA Strong Buy
- Analyst Count
- WSBF 0
- VNDA 3
- Target Price
- WSBF N/A
- VNDA $14.00
- AVG Volume (30 Days)
- WSBF 41.6K
- VNDA 993.5K
- Earning Date
- WSBF 10-23-2025
- VNDA 10-29-2025
- Dividend Yield
- WSBF 3.81%
- VNDA N/A
- EPS Growth
- WSBF 87.32
- VNDA N/A
- EPS
- WSBF 1.32
- VNDA N/A
- Revenue
- WSBF $137,060,000.00
- VNDA $212,074,000.00
- Revenue This Year
- WSBF N/A
- VNDA $14.32
- Revenue Next Year
- WSBF N/A
- VNDA $37.05
- P/E Ratio
- WSBF $11.91
- VNDA N/A
- Revenue Growth
- WSBF 2.87
- VNDA 11.12
- 52 Week Low
- WSBF $11.61
- VNDA $3.81
- 52 Week High
- WSBF $16.75
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- WSBF 59.58
- VNDA 60.60
- Support Level
- WSBF $15.11
- VNDA $4.72
- Resistance Level
- WSBF $15.98
- VNDA $5.46
- Average True Range (ATR)
- WSBF 0.29
- VNDA 0.24
- MACD
- WSBF 0.03
- VNDA 0.09
- Stochastic Oscillator
- WSBF 73.56
- VNDA 86.13
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.